Author Archive

Fulminant Lyme Myocarditis Without Any Other Signs of Lyme Disease in 37 Year Old With Microscopic Polyangiitis – Case Report

https://pubmed.ncbi.nlm.nih.gov/35291336/

Fulminant Lyme myocarditis without any other signs of Lyme disease in a 37-year-old male patient with microscopic polyangiitis-a case report

Marco R Schroeter  1 , Karin Klingel  2 , Peter Korsten  3 , Gerd Hasenfuß  1

Free PMC article

Abstract

Background: Lyme disease is a tick-borne multisystem infection. The most common cardiac manifestation is an acute presentation of Lyme carditis, which often manifests as conduction disorder and rarely as myocarditis.

Case summary: We report the case of a 37-year-old male with a history of microscopic polyangiitis (blood vessel inflammation or vasculitis) receiving immunosuppressive therapy. He was admitted for severe dyspnoea secondary to acute heart failure. Echocardiography and cardiac magnetic resonance imaging indicated a severely reduced left ventricular ejection fraction (LVEF) with global hypokinesia. Coronary heart disease was excluded, and endomyocardial biopsies (EMB) were performed. The left ventricular EMB revealed a rare case of fulminant Lyme carditis with evidence of typical lymphocytic myocarditis. Borrelia afzelii-DNA was detected without any relevant atrioventricular blockage or systemic signs of Lyme disease. The patient had no clinically apparent tick-borne infection or self-reported history of a tick bite. Immunological testing revealed a positive ELISA and Immunoblot for anti-Borrelia immunoglobulin G antibodies. After specific intravenous antibiotic therapy and optimized medical therapy for heart failure, the LVEF recovered, and the patient could be discharged in an improved condition. Repeat EMB a few months later revealed a dramatic regression of the cardiac inflammation and absence of Borrelia DNA in the myocardium.

Discussion: A severely reduced LVEF can be the primary manifestation of Lyme disease even without typical systemic findings and can have a favourable prognosis with antibiotic treatment. A thorough workup for Lyme carditis is required in patients with unexplained heart failure, particularly with EMB, especially in immunosuppressed patients.

For more:

Category:

Heart Issues, Lyme, research

Borrelia Miyamotoi Found in 3-5% of New England Blood Samples = Tens of Thousands Possibly Infected

https://www.futurity.org/borrelia-miyamotoi-new-england-ticks-2716322-2/

Another tick bacteria turns up in New England blood samples

March 25th, 2022 Posted by

Human blood samples from across New England show evidence of Borrelia miyamotoi, a relative of the bacteria that causes Lyme disease.

The findings add important new details to understanding the bacteria species, Borrelia miyamotoi, which was only recently found to infect humans. The tiny species is transmitted by the same deer ticks that carry the Lyme disease pathogen, and can cause meningoencephalitis and relapsing fevers.

“We thought that Borrelia miyamotoi, because it was so recently discovered, would have been more locally confined,” says Peter Krause, senior research scientist at the Yale School of Public Health and senior author of the study. “To our surprise, it was found at all our testing sites throughout New England.”

Krause and Durland Fish, professor emeritus of epidemiology (microbial diseases), were part of a team of researchers who first discovered Borrelia miyamotoi’s ability to infect humans in 2011. Graduate student researcher Demerise Johnston is first author of the new study in the journal Clinical Infectious Diseases.

By testing more than 1,100 blood samples gathered from states across New England in 2018, the team of researchers discovered that almost 3% of the study subjects showed evidence of an immune response (antibody) to Borrelia miyamotoi, with some collection sites demonstrating as much as 5%. These samples were so geographically dispersed in New England that the researchers were unable to determine whether the origin of the infection was southeastern New England, as is the case for Lyme disease and babesiosis, another tick-borne infection.

The proportion of samples containing Borrelia miyamotoi antibody was low compared to that of Lyme disease pathogen, which reached more than 15% in some areas. But Krause says the level of Borrelia miyamotoi antibodies found in the samples indicates that physicians should keep an eye out for the bacteria in patients who present with Lyme disease-like symptoms.

“We’re talking about the possibility of tens of thousands of New England residents becoming infected with Borrelia miyamotoi based on what we found,” he says. “I think it’s important for people to realize that this disease is out there.”

For the study, the researchers also looked into the prevalence of another microorganism, Babesia microti, in their samples. That species is the primary cause of human babesiosis, and it can be spread through ticks just like the other two. Their analysis suggested that around 10% of the samples showed evidence of antibodies against this pathogen. These infections can be transmitted at the same time and coinfection is possible.

“Still, Lyme predominates, but the gap is not as great as is assumed,” Krause says. “There’s more Babesia infections than people realize. Physicians working in areas where babesiosis occurs should be aware of the disease and test for it when patients have consistent symptoms.”

Borrelia miyamotoi disease is much less frequent than those for the microbial species that cause Lyme disease and babesiosis. Krause says there are dependable treatment strategies that can cure individuals who have Borrelia miyamotoi infection. Those strategies involve essentially the same antibiotic treatments that treat Lyme disease. He and his colleagues say in the study that tracking the geographic spread of the species could help health care workers be on alert for potential transmission through ticks and possibly through blood transfusions, although additional studies are needed to confirm that this could happen.

Coauthors are from the Laboratory of Emerging Pathogens at the US Food and Drug Administration and L2 Diagnostics in New Haven, Connecticut.

Source: Matt Kristofferson for Yale University

Category:

Borrelia Miyamotoi (Relapsing Fever Group), Lyme, research, Treatment

2 Minutes of Truth on COVID Shots – Dr. Zelenko & Steve Kirsch

https://rumble.com/vy8swt-premeditated-mass-murder-evidence-suggests-the-fda-and-pfizer-were-aware-of  Video Here (Approx. 2  Min)

“Premeditated Mass Murder” Evidence Suggests FDA & Pfizer Completely Aware of What Would Happen

Dr. Zelenko presents leaked FDA information on mRNA shots.

The FDA had a leaked internal presentation detailing severe side effects two months prior to “vaccine” rollout and Pfizer’s data correlates with the FDA’s.

“There’s a term for this: when there’s 100% correlation. What, the FDA has prophetic powers? So let me tell you what it is: it’s first-degree premeditated mass murder, crimes against humanity, and genocide.” ~ Dr. Zelenko

COVID shots are linked to:

https://mobile.twitter.com/lakovosjustice/status/1507554765106028550  Video Here (Approx. 2 Min)

Steve Kirsch Speaks at U.S. Senate Hearing

U.S. Senate expert witness testimony states that there are 410,000 unexplained deaths in Americans. Insurance company data shows 40% increase in deaths of people under 64. This is the greatest killer of mankind. This is the worse coverup in human history.

For more:

The correlation to the COVID-19 shots now is irrefutable, just from using the U.S. Government’s own data from the CDC, and also from the Vaccine Adverse Events Reporting System (VAERS).

Category:

Activism, vaccines, Viruses

Naltrexone for Long COVID

https://www.theepochtimes.com/how-a-drug-for-opioid-and-alcohol-addiction-is-helping-treat-long-covid

How a Drug for Opioid and Alcohol Addiction Is Helping Treat Long COVID

By Meiling Lee
March 26, 2022 Updated: March 26, 2022

A drug that’s helping millions of people with opioid or alcohol dependence is also being used to treat those suffering symptoms of long COVID.

Naltrexone has been around since 1984 to treat opioid or alcohol addiction. Given in high doses of 50-milligram tablets or a 380-milligram intramuscular injection, the drug works by binding to opioid receptors in the brain to block the effects—especially the urges and cravings to use—of opioids and alcohol.

Naltrexone has also been found to treat other disorders when administered in low doses. It is used off-label to treat obesity, nerve pain, anxiety, and autoimmune disorders.

“I found it very effective in my patients with rheumatoid arthritis, with Crohn’s disease, with other autoimmune processes, and chronic fatigue syndrome,” Dr. Keith Berkowitz, an internist, told The Epoch Times.

Naltrexone is given at doses of 0.5 to 4.5 milligram for patients with long COVID, along with other repurposed medications like prednisone, ivermectin, and vitamin D, according to Berkowitz. At low doses, naltrexone has a potent anti-inflammatory effect, as well as an endorphin effect. (See link for article)

___________________

SUMMARY:
  • The addition of naltrexone to FLCCC’s treatment protocol has been a “game-changer” for patients struggling with long COVID-19
  • One doctor states patients with long COVID aren’t believed by other doctors for it.
  • WHO published a clinical case definition of long COVID as symptoms that occur 3 months from onset of COVID-19 with symptoms and that last for at least 2 months and cannot be explained by an alternative diagnosis.
  • The CDC defines long COVID as a “wide range of new, returning, or ongoing health problems people can experience four or more weeks after first being infected” with SARS-CoV-2.
  • FLCCC and other experts recognize long COVID can happen not only after infection but after a COVID shot.
  • It is believed prolonged exposure to spike proteins and lipid nanoparticles produces chronic inflammation causing long COVID. Circulation Research demonstrated the spike protein was able to damage the cells of the vascular system, and that COVID-19 is a vascular disease rather than a respiratory illness.
  • Another study (pdf)—waiting to be peer-reviewed found that people who received “two doses of COVID-19 shots had higher odds of developing Long COVID.”
  • Another study found that the spike protein from the shots persis in the body & remains in lymph node germinal centers for 60 days after the second dose of an mRNA shot.
  • On expert states the more exposure an individual has to the spike protein, the more symptoms they will likely experience.
  • Brain fog is a long COVID symptom that can be so debilitating patients aren’t able to work.
  • Cognitive dysfunction, another long COVID symptom is one of the most frequent persistent symptoms reported, & occurs in 70 percent of long COVID patients. Brain fog, memory issues, and speech and language problems occurred more often at eight weeks or later than during initial infection, and about 86% of participants reported being unable to work due to cognitive dysfunction and/or memory loss, according to a study.
  • Interleukin 6 (IL-6) causes damage … and low dose naltrexone helps modulate it and nuclear factor kappa B protein, or the inflammatory pathway, Dr. Mobeen Syed said in a video presentation on naltrexone.
Naltrexone is often used with Lyme/MSIDS patients as well.  For more:

Category:

Treatment, Viruses

Growing Evidence of Lyme-Like Illness in Australia

Growing Evidence of an Emerging Tick-borne Disease That Causes a Lyme-like Illness For Many Australia Patients

Professor Noel. Campbell
Fellow Australasian College of Nutritional and Environmental Medicine

sub1281_Campbell (1)  372 page Paper Here

Executive Summary:  

Over the past three decades, thousands of Australian families have felt the impact of Lyme and  other tick-borne diseases (TBDs), with an estimated 10,000 individuals affected each year. Whether  it is a laborer who cannot continue his work because of debilitating joint pain, or a child who  misses school because of debilitating fatigue, pain and cognitive dysfunction, TBDs can have a  significant effect on the day to day lives of Australians. Since Lyme disease was first identified in  Australia in 1982, the disease has spread geographically, and in severity. It has been documented  that there has been an increase in tickborne diseases in Australia, including early and late forms, as  well as an increase in neurological cases.

The patient experience may be characterized by delays in diagnosis, confusion, frustration,  ongoing illness, with, in many cases poor outcomes, disability and a significant financial burden.  (Most recently, we have started to record deaths in Australia from tickborne diseases.)

Recognizing these facts, the Parliament of Australia has referred these matters to the Senate  Community Affairs References committee for enquiry and report. The Senate acknowledged the significant toll TBDs may exact on individuals, families, communities, and the state, noting that  TBDs pose a serious threat to the health and quality of life of many residents and visitors to  Australia.

The purpose of this inquiry should be to establish a Lyme and related tickborne diseases task force charged with exploring and identifying recommendations related to education and awareness, long term effects of misdiagnosis, prevention, and surveillance. The intent of the recommendations are  generally to improve Australia’s response to the tickborne disease burden.

This submission reflects the history of TBDs in Australia, and includes specific recommendations as well as implementation strategies, case studies, and resource needs. While the Senate Inquiry  will be the result of months of research and co-collaboration, it is clear that its report is merely the  beginning of a much-needed dialogue and structured planning process across the country.

The primary recommendations in this submission focus on increased and improve surveillance,  prevention of tick exposure strategies and tactics, as well as education and awareness for  healthcare practitioners(HCPs), patients, the general public and other stakeholders.

In contemplating each recommendation, the author carefully considered each of the countries key  stakeholders, including patients of all ages and their families, vulnerable populations, health care  providers, domestic animals, researchers, Government agencies, policy makers, schools and  community organisations, and the general public.

Key Themes: 

  1. Tickborne disease knowledge and research is evolving rapidly. It will be vital to encourage  critical research, to understand the scope and scale of Lyme and other TBDs in Australia,  and to develop options to improve the public health response and the community/ patient  outcomes.
  2. Different schools of thought exist among all stakeholders regarding Lyme. Ambiguities do  exist so it is important to promote a strong and academically rigourous pursuit of better  research to help clarify the best options for patients. We are encouraged to keep an open  mind, and to continue to explore the nature of these diseases and their health impacts.
  3. The most critical research gap is the lack of a gold standard test for Lyme and other  tickborne infections; a test that can quickly and accurately diagnose the disease, and prove  or disprove ongoing persistence. Research into bio- resonance for diagnosis and treatment of Lyme disease is producing encouraging results in Melbourne Australia.
  1. Without more research and surveillance, it will be difficult to stay ahead of this rapidly  evolving public health problem.
  2. The cost to Australia of doing nothing is considerable.
  3. Without targeted and significant funding, it is unlikely these recommendations can be  deployed in an effective and impactful way.
  4. Collaboration among the commonwealth’s diverse stakeholders Will help ensure programs  and strategies are innovative, effective, and measurable.  Too many Australians have suffered the consequences of Lyme and TBD’s, and without action,  thousands more remain at risk. This is important public health challenge affects all Australians  -every state has reported ticks infected with bacteria. And yet our children, our elderly, and our immunocompromised are most at risk and most vulnerable to their impact. Our actions now,  will significantly impact Australian youth’s risk and future potential.The author respectfully requests Swift action on the enclose recommendations by all state  leaders charged with ensuring the protection and well being of the Commonwealth’s residents.

_________________

For more:

Category:

Activism, Lyme, research, Testing, Ticks